Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes

Stem Cells

Volumn 32, Issue 4, 2014, Pages 983-997

  Elmageed, Zakaria Y Abd ^a   Yang, Yijun ^a   Thomas, Raju ^a,b   Ranjan, Manish ^a   Mondal, Debasis ^a   Moroz, Krzysztof ^a,b   Fang, Zhide ^c   Rezk, Bashir M ^a   Moparty, Krishnarao ^a,d   Sikka, Suresh C ^a   Sartor, Oliver ^a,b   Abdel Mageed, Asim B ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Exosomes; OncomiRNAs; Patient adipose derived stem cells; Prostate cancer; Tumor mimicry

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 130B; MICRORNA 155; RAB PROTEIN; RAB PROTEIN 11A; RAB PROTEIN 1A; RAB PROTEIN 1B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; RNA; TUMOR PROTEIN;

ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE H RAS; ONCOGENE K RAS; PROSTATE CANCER; PROSTATE TUMOR; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ADIPOSE TISSUE; CELL COMMUNICATION; CELL TRANSFORMATION; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; STEM CELL;

ADIPOSE TISSUE; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; EXOSOMES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RNA, NEOPLASM; STEM CELLS;

EID: 84896323201     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1619     Document Type: Article

References (54)

1. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
2. Keto CJ, Aronson WJ, Terris MK, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: Results from the SEARCH database. BJU Int 2012; 110: 492-498.
3. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: Physiological and therapeutic perspectives. Circulation 2004; 109: 656-663.
4. Ma L, Yang Y, Sikka SC, et al. Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proc Natl Acad Sci USA 2012; 109: 2090-2095.
5. Klopp AH, Gupta A, Spaeth E, et al. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth Stem Cells 2011; 29: 11-19.
6. Huelsken J,. Tissue-specific stem cells: Friend or foe Cell Res 2009; 19: 279-281.
7. Bellows CF, Zhang Y, Chen J, et al. Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011; 20: 2461-2468.
8. Brennen WN, Chen S, Denmeade SR, et al. Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 2013; 4: 106-117.
9. Lee Y, El Andaloussi S, Wood MJ,. Exosomes and microvesicles: Extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 15: R125-R134.
10. Thery C, Zitvogel L, Amigorena S,. Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
11. Lakkaraju A, Rodriguez-Boulan E,. Itinerant exosomes: Emerging roles in cell and tissue polarity. Trends Cell Biol 2008; 18: 199-209.
12. Hugel B, Martinez MC, Kunzelmann C, et al. Membrane microparticles: Two sides of the coin. Physiology (Bethesda) 2005; 20: 22-27.
13. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
14. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18: 883-891.
15. Bartel DP,. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233.
16. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46.
17. Eis PS, Tam W, Sun L, Chadburn A, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627-3632.
18. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
19. Graham TR, Agrawal KC, Abdel-Mageed AB,. Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cancer Sci 2009; 101: 103-111.
20. Abd Elmageed ZY, Moroz K, Srivastav SK, et al. High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: Implications for racial disparity of prostate cancer. Carcinogenesis 2013; 34: 2017-2023.
21. Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006; 176: 1375-1385.
22. Dubochet J, Adrian M, Chang JJ, et al. Cryo-electron microscopy of vitrified specimens. Q Rev Biophys 1988; 21: 129-228.
23. Abdel-Mageed AB, Agrawal KC,. Activation of nuclear factor kappaB: Potential role in metallothionein-mediated mitogenic response. Cancer Res 1998; 58: 2335-2338.
24. Segers VF, Lee RT,. Stem-cell therapy for cardiac disease. Nature 2008; 451: 937-942.
25. Collas P,. Programming differentiation potential in mesenchymal stem cells. Epigenetics 2010; 5: 476-482.
26. Taylor DD, Lyons KS, Gercel-Taylor C,. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 2002; 84: 443-448.
27. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
28. Tsouma A, Aggeli C, Pissimissis N, et al. Circulating tumor cells in colorectal cancer: Detection methods and clinical significance. Anticancer Res 2008; 28: 3945-3960.
29. Yao D, Dai C, Peng S,. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 2011; 9: 1608-1620.
30. Oltean S, Sorg BS, Albrecht T, et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 2006; 103: 14116-14123.
31. Kang Y, Massague J,. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004; 118: 277-279.
32. Rak J, Guha A,. Extracellular vesicles vehicles that spread cancer genes. Bioessays 2012; 34: 489-497.
33. Zomer A, Vendrig T, Hopmans ES, et al. Exosomes: Fit to deliver small RNA. Commun Integ Biol 2010; 3: 447-450.
34. Shen Y, Lu Y, Yin X, et al. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogene 2010; 198: 35-39.
35. Rajesh D, Schell K, Verma AK,. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol 1999; 56: 515-525.
36. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
37. Raptis L, Marcellus R, Corbley MJ, et al. Cellular ras gene activity is required for full neoplastic transformation by polyomavirus J Virol 1991; 65: 5203-5210.
38. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
39. Parda DS, Thraves PJ, Kuettel MR, et al. Neoplastic transformation of a human prostate epithelial cell line by the v-Ki-ras oncogene. Prostate 1993; 23: 91-98.
40. Novick P, Brennwald P,. Friends and family: The role of the Rab GTPases in vesicular traffic. Cell 1993; 75: 597-601.
41. Shimada K, Uzawa K, Kato M, et al. Aberrant expression of RAB1A in human tongue cancer. Br J Cancer 2005; 92: 1915-1921.
42. He H, Dai F, Yu L, et al. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr 2002; 10: 231-242.
43. Palmieri D, Bouadis A, Ronchetti R, et al. Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat 2006; 100: 127-137.
44. Sevli S, Uzumcu A, Solak M, et al. The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 208-217.
45. Lai KW, Koh KX, Loh M, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 2010; 46: 1456-1463.
46. Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
47. Bousquet M, Harris MH, Zhou B, et al. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010; 107: 21558-21563.
48. Shi XB, Xue L, Ma AH, et al. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71: 538-549.
49. Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869-17879.
50. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-7029.
51. Li Y, Pei J, Xia H, et al. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003; 22: 4398-4405.
52. Schmid T, Jansen AP, Baker AR, et al. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 2008; 68: 1254-1260.
53. Le MT, Teh, C, Shyh-Chang, N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23: 862-876.
54. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-16175.